<DOCUMENT>
<TYPE>EX-99.15 OTH FIN ST
<SEQUENCE>2
<FILENAME>results.txt
<TEXT>
Exhibit 99.15
Johnson & Johnson Reports 2005 First Quarter EPS Rose 16.9%
on Sales Increase of 11.0%
New Brunswick, NJ (April 19, 2005) - Johnson & Johnson today
announced sales for the first quarter of 2005 of $12.8
billion, an increase of 11.0% over the prior year. The
increase was attributable to operational growth of 8.8% and
a favorable currency impact of 2.2%. Domestic sales were up
4.9%, while international sales increased 20.1%, reflecting
operational growth of 14.7% and a positive currency impact
of 5.4%.

Net earnings and diluted earnings per share for the first
quarter were $2.9 billion and $.97, increases of 17.4% and
16.9%, respectively, as compared with the same period in
2004.

"Our strategic principle of being broadly based continues to
serve us well," said William C. Weldon, Chairman and Chief
Executive Officer. "I'm pleased that the strong performance
of each of the franchises in our Medical Devices and
Diagnostics segment and the solid results in our Consumer
segment were able to add to the more modest increase from
our Pharmaceutical business during the quarter."

Worldwide Medical Devices and Diagnostics sales of $4.8
billion for the first quarter represented an increase over
the prior year of 16.0%, with operational growth of 13.4%
and a positive impact from currency of 2.6%. Domestic sales
increased 7.6%, while international sales increased 25.4%
(19.9% from operations and 5.5% from currency).

All franchises were contributors to the operational growth,
which included DePuy's orthopaedic joint reconstruction and
spinal products; LifeScan's blood glucose monitoring
products; Vistakon's disposable contact lenses; Ortho-
Clinical Diagnostics' professional diagnostic products;
Ethicon's wound care and women's health products; Ethicon
Endo-Surgery's minimally invasive products, and Cordis'
circulatory disease management products.

During the quarter, the Company announced that it had
entered into a definitive agreement to acquire CLOSURE
Medical Corporation, a global leader in biomaterial-based
medical devices.

Worldwide Pharmaceutical sales of $5.8 billion for the first
quarter represented an increase over the prior year of 7.0%,
with operational growth of 5.3% and a positive impact from
currency of 1.7%. Domestic sales increased 3.8%, while
international sales increased 13.8% (8.5% from operations
and 5.3% from currency).

Sales growth reflects the strong performance of REMICADEr
(infliximab), a treatment for rheumatoid arthritis, Crohn's
disease and ankylosing spondylitis; TOPAMAXr (topiramate),
an antiepileptic and a treatment for the prevention of
migraine headaches; RISPERDALr (risperidone) and RISPERDALr
CONSTAT (risperidone), an antipsychotic medication;
LEVAQUINr (levofloxacin), an anti-infective; CONCERTAr
(methylphenidate HCl), a treatment for attention deficit
hyperactivity disorder and ACIPHEXr/PARIETT (rabeprazole
sodium), a proton pump inhibitor for gastrointestinal
disorders. PROCRITr/EPREXr (Epoetin alfa), a product for the
treatment of anemia, was negatively impacted by competition
and both the hormonal contraceptive franchise and DURAGESICr
(fentanyl transdermal system), a transdermal patch for
chronic pain, were negatively impacted by generic
competition.

In April, the Company announced the completion of its
acquisition of TransForm Pharmaceuticals, Inc., which
specializes in the discovery of superior formulations and
novel crystalline forms of drug molecules. In addition, the
Company submitted a new drug application to the U.S. Food
and Drug Administration (FDA) for REMICADEr (infliximab) for
the treatment of ulcerative colitis.

Worldwide Consumer segment sales of $2.3 billion for the
first quarter represented an increase over the prior year of
11.4%, with operational growth of 8.9% and a positive impact
from currency of 2.5%. Domestic sales increased 3.1%, while
international sales increased 20.7% (15.4% from operations
and 5.3% from currency).

Strong growth in Consumer sales was achieved by McNeil
Consumer & Specialty Pharmaceuticals' over-the-counter adult
TYLENOLr (acetaminophen) products, McNeil Nutritional's
SPLENDAr (sucralose) sweetener and the skin care lines of
RoCr and AVEENOr.

Johnson & Johnson is the world's most comprehensive and
broadly based manufacturer of health care products, as well
as a provider of related services, for the consumer,
pharmaceutical, and medical devices and diagnostics markets.
The more than 200 Johnson & Johnson operating companies
employ approximately 111,000 men and women in 57 countries
and sell products throughout the world.

NOTE TO INVESTORS
Johnson & Johnson will conduct a conference call with
financial analysts to discuss this news release today at
8:30 a.m., Eastern Daylight Savings Time. A simultaneous
webcast of the call for interested investors and others may
be accessed by clicking on the webcast icon from the jnj.com
Homepage or by clicking on Calendar of Events in the
Investor Relations section of the Web site. A replay will be
available approximately two hours after the live webcast by
clicking on "Webcasts/Presentations" in the Investor
Relations section.

(This press release contains "forward-looking statements" as
defined in the Private Securities Litigation Reform Act of
1995. These statements are based on current expectations of
future events. If underlying assumptions prove inaccurate or
unknown risks or uncertainties materialize, actual results
could vary materially from the Company's expectations and
projections. Risks and uncertainties include general
industry conditions and competition; economic conditions,
such as interest rate and currency exchange rate
fluctuations; technological advances and patents attained by
competitors; challenges inherent in new product development,
including obtaining regulatory approvals; domestic and
foreign health care reforms and governmental laws and
regulations; and trends toward health care cost containment.
A further list and description of these risks, uncertainties
and other factors can be found in Exhibit 99(b) of the
Company's Annual Report on Form 10-K for the fiscal year
ended January 2, 2005. Copies of this Form 10-K are
available online at www.sec.gov or on request from the
Company. The Company assumes no obligation to update any
forward-looking statements as a result of new information or
future events or developments.)

For  more information on Johnson & Johnson, please visit the
Company's website at http://www.jnj.com.
</TEXT>
</DOCUMENT>
